These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 18662521)

  • 41. Which statin?
    Med Lett Drugs Ther; 2008 Apr; 50(1284):29-31. PubMed ID: 18425054
    [No Abstract]   [Full Text] [Related]  

  • 42. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 43. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 44. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of aggressive statin therapy.
    Conn Med; 2005; 69(6):339-41. PubMed ID: 16184860
    [No Abstract]   [Full Text] [Related]  

  • 46. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 49. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?
    Rizzo M; Berneis K; Spinas GA; Rini GB; Kapur NK
    Int J Clin Pract; 2009 Mar; 63(3):478-85. PubMed ID: 19222633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statin use and the risk of age related macular degeneration in a large health organization in Israel.
    Shalev V; Sror M; Goldshtein I; Kokia E; Chodick G
    Ophthalmic Epidemiol; 2011 Apr; 18(2):83-90. PubMed ID: 21401416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statin therapy: more than meets the eye?
    McCain J
    Manag Care; 2004 Apr; 13(4):40-9. PubMed ID: 15146720
    [No Abstract]   [Full Text] [Related]  

  • 52. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence.
    Davidson MH
    J Clin Lipidol; 2010; 4(1):72-3; discussion 74. PubMed ID: 21122630
    [No Abstract]   [Full Text] [Related]  

  • 53. Statin therapy in patients with type 2 diabetes.
    Lo V; Noviasky J; Nashelsky J
    Am Fam Physician; 2005 Sep; 72(5):866-8. PubMed ID: 16156346
    [No Abstract]   [Full Text] [Related]  

  • 54. [Pleiotropic effects of statins].
    Palomäki A
    Duodecim; 2004; 120(4):411-8. PubMed ID: 15065459
    [No Abstract]   [Full Text] [Related]  

  • 55. Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidence.
    Gosmanov AR
    J Clin Lipidol; 2010; 4(1):69-71; discussion 74. PubMed ID: 21122629
    [No Abstract]   [Full Text] [Related]  

  • 56. Don't trust an LDL over 70?
    Aronow WS
    Geriatrics; 2004 May; 59(5):12-3. PubMed ID: 15152729
    [No Abstract]   [Full Text] [Related]  

  • 57. Beyond statins: lipid management to reduce cardiovascular risk.
    Schuck RN; Mendys PM; Simpson RJ
    Pharmacotherapy; 2013 Jul; 33(7):754-64. PubMed ID: 23606278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Not just decreased LDL level is decisive. Which statin for patients at risk for coronary disease?].
    MMW Fortschr Med; 2004 Jun; 146(24):1-3. PubMed ID: 15366507
    [No Abstract]   [Full Text] [Related]  

  • 59. Are statin effects mediated through, or in spite of, their cholesterol-lowering action?
    Mascitelli L; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(2):262-3. PubMed ID: 19141486
    [No Abstract]   [Full Text] [Related]  

  • 60. [Lipid-lowering therapy in Europe and the United States - treat to target or fire and forget?].
    Pfetsch V; Sanin V; Koenig W
    Dtsch Med Wochenschr; 2016 Jun; 141(12):857-62. PubMed ID: 27305301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.